Literature DB >> 8894582

In vitro susceptibility of pneumococci to trovafloxacin, penicillin G, and other antimicrobial agents in the Czech Republic and Slovakia.

P Urbásková1, J Trupl, H Hupková, P C Appelbaum, M R Jacobs.   

Abstract

The in vitro activity of the new naphthyridone trovafloxacin (CP 99,219) was compared with those of penicillin G and six other agents (cefpodoxime, erythromycin, azithromycin, clindamycin, ciprofloxacin, and sparfloxacin) against 316 penicillin-susceptible and -resistant pneumococci isolated in the former Czechoslovakia. Trovafloxacin was very active against strains of Streptococcus pneumoniae (MIC50 and MIC90 0.25 microgram/ml). Ciprofloxacin was less active (MIC50 1.0 microgram/ml, MIC90 2.0 micrograms/ml), and MICs of sparfloxacin were between those of trovafloxacin and ciprofloxacin (MIC50 and MIC90 both 0.5 microgram/ml). MICs of cefpodoxime, erythromycin, azithromycin, and clindamycin were higher for strains intermediately resistant or resistant to penicillin than for penicillin-susceptible strains.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8894582     DOI: 10.1007/bf01691161

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

Review 1.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

Review 2.  New prospects for antibacterial agents against multidrug-resistant pneumococci.

Authors:  P C Appelbaum
Journal:  Microb Drug Resist       Date:  1995       Impact factor: 3.431

3.  Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  1995-01       Impact factor: 5.790

Review 4.  Management of antibiotic-resistant pneumococcal infections.

Authors:  K P Klugman
Journal:  J Antimicrob Chemother       Date:  1994-08       Impact factor: 5.790

5.  Novel penicillin-resistant clones of Streptococcus pneumoniae in the Czech Republic and in Slovakia.

Authors:  A M Figueiredo; R Austrian; P Urbaskova; L A Teixeira; A Tomasz
Journal:  Microb Drug Resist       Date:  1995       Impact factor: 3.431

Review 6.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

Review 7.  Pneumococcal resistance to antibiotics.

Authors:  K P Klugman
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

8.  Multiple antimicrobial resistance of pneumococci in children with otitis media, bacteremia, and meningitis in Slovakia.

Authors:  M R Reichler; J Rakovsky; A Sobotová; M Sláciková; B Hlavácová; B Hill; L Krajcíková; P Tarina; R R Facklam; R F Breiman
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

  8 in total
  4 in total

Review 1.  Trovafloxacin.

Authors:  M Haria; H M Lamb
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  In vitro susceptibility of 90 penicillin-susceptible and -resistant pneumococci to penicillin G, amoxicillin, amoxicillin/clavulanate, cefaclor, cefuroxime, cefpodoxime, cefixime and imipenem.

Authors:  H Hupková; J Trupl
Journal:  Folia Microbiol (Praha)       Date:  1998       Impact factor: 2.099

3.  Clinical evaluation of the tolerability and efficacy of trovafloxacin compared with sparfloxacin in the treatment of lower respiratory tract infections.

Authors:  J C Shobha; T R Kumar; N Deivanayagam; R B Singh; P Waghray; P A Babu; J Bhaduri; C C Sekhar
Journal:  Clin Drug Investig       Date:  2000       Impact factor: 2.859

Review 4.  Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.

Authors:  J C Pechère; T D Gootz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.